Potential therapeutic interventions for fragile X syndrome
about
Fragile x syndromeMatrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.The pathophysiology of fragile X (and what it teaches us about synapses)Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity, and learning deficits in a fragile X model.Investigating mechanisms underlying neurodevelopmental phenotypes of autistic and intellectual disability disorders: a perspective.CGG repeat in the FMR1 gene: size mattersHyperactivity, perseveration and increased responding during attentional rule acquisition in the Fragile X mouse modelFRAGILE X SYNDROME: PSYCHIATRIC MANIFESTATIONS, ASSESSMENT AND EMERGING THERAPIESSubchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinaseTherapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.FMR1 premutation and full mutation molecular mechanisms related to autism.Targeted treatments for fragile X syndrome.Positron Emission Tomography (PET) Quantification of GABAA Receptors in the Brain of Fragile X Patients.Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities.Signaling defects in iPSC-derived fragile X premutation neuronsThe effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice.TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROMEModeling human neurodevelopmental disorders in the Xenopus tadpole: from mechanisms to therapeutic targets.Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome.Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models.Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome.The challenges of clinical trials in fragile X syndrome.Pathways to drug development for autism spectrum disorders.New perspectives on the biology of fragile X syndromeRoles of toll-like receptors in cancer: a double-edged sword for defense and offense.Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development.Lessons learned from studying syndromic autism spectrum disorders.Real-Time Imaging Reveals Properties of Glutamate-Induced Arc/Arg 3.1 Translation in Neuronal Dendrites.Elevated progranulin contributes to synaptic and learning deficit due to loss of fragile X mental retardation protein.An essential role for UBE2A/HR6A in learning and memory and mGLUR-dependent long-term depression.Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome.Analysis of FMR1 deletion in a subpopulation of post-mitotic neurons in mouse cortex and hippocampus.The quest for targeted therapy in fragile X syndrome.Fragile X syndrome: From protein function to therapy.
P2860
Q24633000-AC49115D-8CAF-4B4A-8CE5-D730ADF984E1Q26853083-39790506-89EA-4EF1-99AE-9F9762D2AB9BQ27010675-0BB89405-5B37-41B0-995F-85C1FA5F5FE2Q30411531-66EFB246-D30D-4B04-9C98-D009B5283E3BQ30447502-90F7DA94-15DD-48F5-8AAD-6EC2B099BE31Q30464036-6D67E4A6-6C70-456F-9F43-29A2E88CAAC6Q30557514-3716E5E1-0742-46A3-BC34-D263BF9A33DAQ35013074-1169D105-9ACF-4C07-B963-2BE399D39AA1Q35188148-8A40616C-49A0-43CE-A55B-C88BFAD147DCQ35232638-3A83679D-C079-4463-B73C-99A4D587E5F2Q35614072-ACC63ABA-63B2-450A-99B7-C8C5A387EAE7Q35680720-202B2D29-7B6D-4A72-9926-E1F1DDEF64B1Q35680726-279F8FE9-9DB9-4A85-94B2-5DB1EFA224B7Q35723110-58228C6B-DB42-4AD7-81F6-2E4E310433C2Q35765423-36A8E955-406A-4133-8278-497EBA3CA7EBQ36142068-1502ADB0-6459-477E-B617-082D50C1F28DQ36379639-8559E7B8-B08D-4487-A94C-A0028EC5BA43Q36399716-B6537A06-09F1-42AE-ACE0-EA93EF5BDE2BQ37137731-60BE4A27-8C84-41FC-9B18-2300515379FDQ37182603-EED916EF-DE61-4EA1-908A-C2D3C5C193B8Q37564195-28BCA36B-9F72-48F2-89D4-EDCDCAB92C16Q37580522-56FF873C-338B-44B6-A67A-E2FA79D51E51Q37598441-B95918E5-ABBA-4405-8F77-D65328F89797Q37972081-9FA22D66-C793-454C-B9CE-C33A31B9CF51Q37989764-D6EB82B5-1B41-4084-B48B-2BA356D7BB5FQ38039958-FB0BFA12-7ABA-4C72-88AE-FC13AFD92A5EQ38162720-7DCB9368-C929-410C-B31B-F908F429DF2CQ38992291-703FE79B-0A5D-4D8A-9DCF-156E201650BDQ41591403-70AA182B-08E6-4A71-B8D1-41A987E47CDBQ47449434-6547A204-7EB3-491D-88BA-D419A9D96C26Q48072395-9DD5057E-F0BA-466B-B280-6E22E072B1F9Q48627146-C9B32153-0691-47FC-B8D8-5975B1064982Q50344832-640B77C2-EC3B-4C59-89B5-905E43096E58Q50346048-1636265C-1328-4E0E-B66D-D4AEF60ECCB7Q54782597-240DE768-EC4B-46EB-8679-B36BF872E8E6
P2860
Potential therapeutic interventions for fragile X syndrome
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Potential therapeutic interventions for fragile X syndrome
@ast
Potential therapeutic interventions for fragile X syndrome
@en
type
label
Potential therapeutic interventions for fragile X syndrome
@ast
Potential therapeutic interventions for fragile X syndrome
@en
prefLabel
Potential therapeutic interventions for fragile X syndrome
@ast
Potential therapeutic interventions for fragile X syndrome
@en
P2093
P2860
P1476
Potential therapeutic interventions for fragile X syndrome
@en
P2093
Ben A Oostra
Femke M S de Vrij
Josien Levenga
Rob Willemsen
P2860
P304
P356
10.1016/J.MOLMED.2010.08.005
P577
2010-09-21T00:00:00Z